Display options
Cite
Pinto C, Cárdenas P, Osses N, et al. Characterization of Wnt/β-catenin and BMP/Smad signaling pathways in an in vitro model of amyotrophic lateral sclerosis. Front Cell Neurosci. 2013;7:239doi: 10.3389/fncel.2013.00239.
Pinto, C., Cárdenas, P., Osses, N., & Henríquez, J. P. (2013). Characterization of Wnt/β-catenin and BMP/Smad signaling pathways in an in vitro model of amyotrophic lateral sclerosis. Frontiers in cellular neuroscience, 7239. https://doi.org/10.3389/fncel.2013.00239
Pinto, Cristina, et al. "Characterization of Wnt/β-catenin and BMP/Smad signaling pathways in an in vitro model of amyotrophic lateral sclerosis." Frontiers in cellular neuroscience vol. 7 (2013): 239. doi: https://doi.org/10.3389/fncel.2013.00239
Pinto C, Cárdenas P, Osses N, Henríquez JP. Characterization of Wnt/β-catenin and BMP/Smad signaling pathways in an in vitro model of amyotrophic lateral sclerosis. Front Cell Neurosci. 2013 Dec 03;7:239. doi: 10.3389/fncel.2013.00239. eCollection 2013. PMID: 24348333; PMCID: PMC3847560.
Copy Download .nbib Format: NLM
Share it on

Front Cell Neurosci. 2013 Dec 03;7:239. doi: 10.3389/fncel.2013.00239. eCollection 2013.

Characterization of Wnt/β-catenin and BMP/Smad signaling pathways in an in vitro model of amyotrophic lateral sclerosis.

Frontiers in cellular neuroscience

Cristina Pinto, Pilar Cárdenas, Nelson Osses, Juan P Henríquez

Affiliations

  1. Laboratory of Developmental Neurobiology, Department of Cell Biology, Faculty of Biological Sciences, Center for Advanced Microscopy, Universidad de Concepción Concepción, Chile.
  2. Institute of Chemistry, Faculty of Sciences, Pontificia Universidad Católica de Valparaíso Valparaiso, Chile.

PMID: 24348333 PMCID: PMC3847560 DOI: 10.3389/fncel.2013.00239

Abstract

Different pathways activated by morphogens of the early embryonic development, such as the Wnt and the Bone Morphogenetic Protein (BMP) ligands, are involved in diverse physiological and pathological conditions of the nervous system, including neurodegeneration. In this work, we have analyzed the endogenous activity of the canonical Wnt/β-catenin and BMP/Smad-dependent pathways in an in vitro model of amyotrophic lateral sclerosis (ALS), given by motor neuron-like NSC34 cells stably expressing wild-type or G93A mutated forms of human Cu/Zn superoxide dismutase-1 (SOD1). As ALS-derived motor neurons, NSC34 cells expressing mutated hSOD1 show a decreased proliferation rate, are more susceptible to oxidation-induced cell death and display Golgi fragmentation. In addition, they display an impaired ability to induce the expression of the motor neuronal marker Hb9 and, consistently, to morphologically differentiate into a motor neuronal phenotype. Regarding signaling, our data show that the transcriptional activity associated to the Wnt/β-catenin pathway is decreased, a finding possibly associated to the cytosolic aggregation of β-catenin. In turn, the BMP-dependent phosphorylation of Smad1 and the transcriptional activation of the BMP/Smad pathway is increased in the pathologic model. Together, these findings suggest that Wnt/β-catenin and the BMP-dependent pathways could play relevant roles in the neurodegeneration of motor neurons in the context of ALS.

Keywords: ALS; BMP; Wnt; beta catenin; motor neurons; smad proteins

References

  1. Proteomics. 2010 May;10(9):1886-90 - PubMed
  2. Int J Dev Neurosci. 2002 Oct;20(6):521-6 - PubMed
  3. Science. 1998 Sep 18;281(5384):1851-4 - PubMed
  4. Mol Neurodegener. 2010 Jan 18;5:3 - PubMed
  5. EMBO J. 2010 Jul 21;29(14):2433-45 - PubMed
  6. Mol Neurodegener. 2011 Jul 13;6:49 - PubMed
  7. Int J Clin Exp Pathol. 2013 Jun 15;6(7):1245-60 - PubMed
  8. Dev Dyn. 1992 Jul;194(3):209-21 - PubMed
  9. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7753-7 - PubMed
  10. Cold Spring Harb Perspect Biol. 2012 Feb 01;4(2): - PubMed
  11. PLoS One. 2013 May 28;8(5):e64720 - PubMed
  12. Expert Rev Mol Med. 2006 May 24;8(11):1-22 - PubMed
  13. PLoS One. 2008 Jun 04;3(6):e2334 - PubMed
  14. FASEB J. 2002 Dec;16(14):1982-4 - PubMed
  15. EMBO J. 2004 Sep 1;23(17):3527-37 - PubMed
  16. J Biol Chem. 2006 Aug 11;281(32):22429-33 - PubMed
  17. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15763-8 - PubMed
  18. Acta Neuropathol. 2006 Dec;112(6):673-80 - PubMed
  19. Nat Rev Neurol. 2011 Sep 27;7(11):650-4 - PubMed
  20. Neurochem Int. 2013 Jun;62(8):1029-38 - PubMed
  21. Biotechnol Lett. 2008 Apr;30(4):603-10 - PubMed
  22. Neurol Res. 2012 May;34(4):390-9 - PubMed
  23. J Neurosci. 2011 Jun 29;31(26):9466-71 - PubMed
  24. Bioessays. 2012 Nov;34(11):953-62 - PubMed
  25. J Neurochem. 2012 Aug;122(3):594-604 - PubMed
  26. J Biol Chem. 2002 Feb 1;277(5):3176-85 - PubMed
  27. Exp Cell Res. 2004 Jul 1;297(1):186-96 - PubMed
  28. J Biomed Mater Res A. 2012 Nov;100(11):3008-19 - PubMed
  29. Nat Rev Neurosci. 2013 Apr;14(4):248-64 - PubMed
  30. J R Soc Interface. 2012 Sep 7;9(74):2017-32 - PubMed
  31. J Neurochem. 2008 May;105(4):1471-9 - PubMed
  32. Science. 1992 Jun 12;256(5063):1555-60 - PubMed
  33. Cell. 2003 Jun 13;113(6):685-700 - PubMed
  34. Science. 1994 Jun 17;264(5166):1772-5 - PubMed
  35. Colloids Surf B Biointerfaces. 2012 May 1;93:85-91 - PubMed
  36. Nature. 1993 Mar 4;362(6415):59-62 - PubMed
  37. Mol Psychiatry. 2003 Feb;8(2):195-208 - PubMed
  38. Cell. 1996 Jan 26;84(2):309-20 - PubMed
  39. Annu Rev Neurosci. 2004;27:723-49 - PubMed
  40. J Biol Chem. 2013 May 31;288(22):15699-711 - PubMed
  41. Neuron. 1999 Aug;23(4):659-74 - PubMed
  42. Biometals. 2011 Apr;24(2):269-78 - PubMed
  43. Biotechnol Lett. 2013 Aug;35(8):1199-207 - PubMed
  44. Cell. 2003 Oct 31;115(3):281-92 - PubMed
  45. Cell. 1998 Oct 2;95(1):67-80 - PubMed
  46. J Cell Biochem. 2012 Nov;113(11):3301-12 - PubMed
  47. Br J Oral Maxillofac Surg. 2007 Apr;45(3):197-202 - PubMed
  48. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5165-70 - PubMed
  49. Neurochem Res. 2013 Sep;38(9):1904-13 - PubMed
  50. J Physiol Paris. 2006 Mar-May;99(2-3):211-20 - PubMed
  51. CNS Neurol Disord Drug Targets. 2010 Aug;9(4):504-23 - PubMed
  52. Orphanet J Rare Dis. 2009 Feb 03;4:3 - PubMed
  53. J Neurosci. 2005 Jan 5;25(1):108-17 - PubMed
  54. Nat Rev Neurosci. 2006 Sep;7(9):710-23 - PubMed
  55. Curr Opin Neurobiol. 2011 Feb;21(1):182-8 - PubMed
  56. Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):343-55 - PubMed
  57. Int J Mol Sci. 2011;12(12):8924-46 - PubMed
  58. Hum Mol Genet. 2009 Dec 1;18(23):4552-64 - PubMed
  59. J Mol Neurosci. 2005;25(1):79-94 - PubMed
  60. Prog Neurobiol. 2012 May;97(2):101-26 - PubMed
  61. Cytokine Growth Factor Rev. 2005 Jun;16(3):251-63 - PubMed
  62. Eur J Neurosci. 2013 May;37(10):1550-63 - PubMed
  63. J Biol Chem. 2002 Feb 15;277(7):5330-8 - PubMed
  64. Brain Res Mol Brain Res. 2003 Mar 17;111(1-2):155-64 - PubMed
  65. Cell Mol Life Sci. 2013 Nov;70(21):4181-95 - PubMed
  66. Neurosci Lett. 2007 Nov 20;428(1):43-6 - PubMed
  67. J Neurosci. 2012 Mar 7;32(10):3492-8 - PubMed
  68. Dev Dyn. 2010 Jan;239(1):16-33 - PubMed
  69. Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R233-42 - PubMed
  70. Neuropathol Appl Neurobiol. 2003 Dec;29(6):529-45 - PubMed
  71. Cell Signal. 2011 Apr;23(4):609-20 - PubMed
  72. Nat Rev Neurosci. 2010 Feb;11(2):77-86 - PubMed
  73. Science. 2004 Mar 5;303(5663):1483-7 - PubMed
  74. Am J Pathol. 1994 Jun;144(6):1288-300 - PubMed
  75. Acta Physiol (Oxf). 2012 Jan;204(1):128-36 - PubMed
  76. J Neurochem. 2010 Jul;114(2):408-18 - PubMed

Publication Types